- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- HST Standard
- ID number:
- 6598
Provisional Schedule
- Committee meeting: 1:
- 25 June 2026
- Expected publication:
- 19 August 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email HST@nice.org.uk
- External Assessment Group:
- Bristol Technology Assessment Group, University of Bristol
Stakeholders
- Companies sponsors
- Rhythm Pharmaceuticals
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Bardet-Biedl Syndrome UK
- British Obesity Society
- Professional groups
- Royal College of Physicians
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 December 2025 | Invitation to participate |
| 18 December 2025 | In progress |
| 01 December 2025 - 15 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 05 November 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual